Results 81 to 90 of about 581 (108)

A Sonidegib Experience in the Treatment of Basal Cell Carcinoma with Systemic Lupus Erythematosus: A Case Report

Clinical, Cosmetic and Investigational Dermatology
Liangliang Shi,1,* Binxin Liu,1,* Pengxiang Gao,2 Xianwei Cao,1 Chuan Wan1 1Department of Dermatology, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, People’s Republic of China; 2Department
Shi L, Liu B, Gao P, Cao X, Wan C
doaj  

Alcian blue‐positive stromal phenotype in basal cell carcinoma is associated with progression on first‐line hedgehog inhibitors

The Journal of Pathology: Clinical Research
Basal cell carcinoma (BCC) is the most frequent malignancy in fair‐skinned populations. Although curable in most cases, approximately 4% of patients develop locally advanced or metastatic disease (advBCC) requiring systemic therapy.
Viola K DeTemple, Rudolf Stadler, Sabine Bredemeier, Sungyoung Chung, Katrin Schaper‐Gerhardt, Mareike Alter, Yenny Angela, Henner Stege, Ulrike Leiter, Jan Ohletz, Elisabeth Livingstone, Imke vonWasielewski, Jessica C Hassel, Julia Huynh, Christoffer Gebhardt, Claudia Pföhler, Ralf Gutzmer, Christina H Scheel   +17 more
doaj   +1 more source

Treatment of progressive locally advanced and metastatic basal cell carcinoma after two lines of treatment with hedgehog inhibitors and anti-PD1. the role of sonidegib rechallenge

Treatment of progressive locally advanced and metastatic basal cell carcinoma after two lines of treatment with hedgehog inhibitors and anti-PD1: The role of sonidegib ...
Guida, S, Di Lella, G, Guida S., Ambrosio L., Zalaudek, I, Conforti C., Retrosi C., Pellacani, G, Giuffrida, R, Longo, C, Zalaudek I., Agozzino M., Di Lella G., di Meo N., Cantisani, C, Agozzino, M, Ambrosio, L, Conforti, C, Giuffrida R., Retrosi, C, Longo C., Lembo, S, Pellacani G., di Meo, N, Lembo S., Cantisani C., Cantisani, C., di Meo, N., Ambrosio, L., Di Lella, G., Longo, C., Pellacani, G., Zalaudek, I., Agozzino, M., Retrosi, C., Guida, S., Lembo, S., Conforti, C., Giuffrida, R.   +38 more
core   +1 more source

Sonidegib Therapy for Locally Advanced Basal Cell Carcinoma in an Elderly Patient: A Case Report

Clinical, Cosmetic and Investigational Dermatology
Yuyu Deng,1– 5 Pingxiu He,1– 5 Changxia Li,1– 5 Guolan Li,1– 5 Xiaohua Tao1– 5 1Dermatology Department, Dermatology Hospital of Jiangxi Province, Nanchang, Jiangxi, People’s Republic of China; 2Dermatology Department, Jiangxi Provincial Clinical Research
Deng Y, He P, Li C, Li G, Tao X
doaj  

Refractory Morpheaform Basal Cell Carcinoma Successfully Treated with Oral Sonidegib

Clinical, Cosmetic and Investigational Dermatology
Yuesen Zhang,1,* Junyou Zheng,2,* Xiaofang Li,3 Yan Wang,1 Fang Fang,1 Zhiwen Wang,1 Wenbo Bu1 1Department of Dermatologic Surgery, Hospital for Skin Diseases, Institute of Dermatology, Chinese Academy of Medical Sciences and Peking Union
Zhang Y, Zheng J, Li X, Wang Y, Fang F, Wang Z, Bu W   +6 more
doaj  

Dynamic optical coherence tomography evaluation in locally advanced basal cell carcinoma during sonidegib treatment

BackgroundBasal cell carcinoma (BCC) is the most common cancer in the Caucasian population. It has a multifactorial pathogenesis, in which constitutive activation of the Sonic Hedgehog signalling (SHH) pathway (via mutations in PTCH1 or SMO genes ...
Di Guardo, A, Cantisani, C, Musolff, N, Paolino, G, Azzella, G, Rossi, G, Sasso, F, Rega, F, Pellacani, G, Bánvölgyiv, A, Farnetani, F, Longo, C, Rovaldi, E   +12 more
core   +1 more source

Sonidegib (LDE225) Reduces Inflammatory Signaling and Preserves Taste Buds in a Sepsis Mouse Model

Background: Sepsis triggers a complex and widespread inflammatory response that disrupts multiple organ systems, including the taste organ. Loss of taste is a symptom recognized in sepsis survivors and has the potential to contribute to further ...
Nawaz, Isaiah, McClelland, Ashlyn, Khikmatov, Murod, Audu, Gabrielle, Kumari, Archana, Yin, Kingsley   +5 more
core  

Long-term efficacy and safety of sonidegib in patients with locally advanced and metastatic basal cell carcinoma: 30-month analysis of the randomized phase 2 BOLT study

, 2018
Background: Patients with locally advanced basal cell carcinoma (laBCC) or metastatic BCC (mBCC), two difficult-to-treat populations, have had limited treatment options.
Plummer, R., Yi, T., Mone, M., Dummer, R., Zhou, J., Kudchadkar, R., Guminski, A., Castro, H., Migden, M.R., Chang, A.L.S., Trefzer, U., Loquai, C., Lewis, K.D., Dirix, L., Combemale, P., Lear, J.T., Gutzmer, R., Kaatz, M., Stratigos, A., Sellami, D.   +19 more
core  

Intracranial regression of an advanced basal cell carcinoma using sonidegib and itraconazole after failure with vismodegib

JAAD Case Reports, 2018
Jaeyoung Yoon, MD, PhD, Anthony J. Apicelli, III, MD, PhD, Tricia V. Pavlopoulos, MD   +2 more
doaj   +1 more source

Neoadjuvant Hedgehog Inhibitors for Locally Advanced Basal Cell Carcinoma: Insights from Two Real-world Cases

Acta Dermato-Venereologica
Paolo Antonetti, Ettore Lupi, Irene Tucceri Cimini, Maria Esposito, Maria Concetta Fargnoli   +4 more
doaj   +1 more source